If you've got the perfect spot to grow a beautiful vining plant, it's important to know which ones support the ecosystem and ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

Therapeutics announced that it has commenced an underwritten public offering. All shares are being offered by Akebia. Leerink ...

Akebia Therapeutics shares were down 20% to $2.27 after the company priced its underwritten public offering of 25 million shares at $2 a share. All shares are being offered by Akebia. The proceeds to ...

The shares are being offered by Akebia pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on September 3, 2024 and declared effective by the ...

Shares of Akebia Therapeutics fell after the company said it has commenced an underwritten public offering. The stock sank 21% to $2.24 in after-hours trading Wednesday. Shares ended the regular ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a fourth-quarter loss of $22.8 million, after reporting a profit in the same period a year ...

Good day, and welcome to Akebia's fourth-quarter 2024 financial results call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to turn the call over to Mercedes ...